Resveratrol and cardiovascular diseases

Nutrients

Volumn 8, Issue 5, 2016, Pages

  Bonnefont Rousselot, Dominique ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Antioxidant; Atherosclerosis; Clinical; Heart failure; Hypertension; Inflammation; Myocardial infarction; Preclinical; Resveratrol

Indexed keywords

ANTIOXIDANT; BORTEZOMIB; DIMETHYLARGININASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA; N(G),N(G) DIMETHYLARGININE; PICEATANNOL; RESVERATROL; SIRTUIN 1; TRANSCRIPTION FACTOR NRF2; FAT INTAKE; NONSTEROID ANTIINFLAMMATORY AGENT; STILBENE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERTENSION; IN VITRO STUDY; LIPID PEROXIDATION; META ANALYSIS (TOPIC); NONHUMAN; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; ANALYSIS; CARDIOVASCULAR DISEASES; CHEMISTRY; FAT INTAKE; WINE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; DIETARY FATS; HUMANS; STILBENES; WINE;

EID: 84965151035     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu8050250     Document Type: Review

References (161)

1. Laslett, L. J.; Alagona, P., Jr.; Clark, B. A., 3rd; Drozda, J. P., Jr.; Saldivar, F.; Wilson, S. R.; Poe, C.; Hart, M. The worldwide environment of cardiovascular disease: Prevalence, diagnosis, therapy, and policy issues: A report from the American College of Cardiology. J. Am. Coll. Cardiol. 2012, 60, S1-S49. [CrossRef] [PubMed]
2. Renaud, S.; de Lorgeril, M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992, 339, 1523-1526. [CrossRef]
3. Smoliga, J. M.; Baur, J. A.; Hausenblas, H. A. Resveratrol and health-A comprehensive review of human clinical trials. Mol. Nutr. Food Res. 2011, 55, 1129-1141. [CrossRef] [PubMed]
4. Delmas, D.; Jannin, B.; Latruffe, N. Resveratrol: Preventing properties against vascular alterations and ageing. Mol. Nutr. Food Res. 2005, 49, 377-395. [CrossRef] [PubMed]
5. Zordoky, B. N.; Robertson, I. M.; Dyck, J. R. Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. Biochim. Biophys. Acta 2015, 1852, 1155-1177. [CrossRef] [PubMed]
6. Cottart, C. H.; Nivet-Antoine, V.; Beaudeux, J. L. Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. Mol. Nutr. Food Res. 2014, 58, 7-21. [CrossRef] [PubMed]
7. Wallerath, T.; Deckert, G.; Ternes, T.; Anderson, H.; Li, H.; Witte, K.; Förstermann, U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 2002, 106, 1652-1658. [CrossRef] [PubMed]
8. Leikert, J. F.; Räthel, T. R.; Wohlfart, P.; Cheynier, V.; Vollmar, A. M.; Dirsch, V. M. Red wine polyphenols enhance endothelial nitric oxide synthase expression and subsequent nitric oxide release from endothelial cells. Circulation 2002, 106, 1614-1617. [CrossRef] [PubMed]
9. Saad, M. I.; Abdelkhalek, T. M.; Saleh, M. M.; Kamel, M. A.; Youssef, M.; Tawfik, S. H.; Dominguez, H. Insights into the molecular mechanisms of diabetes-induced endothelial dysfunction: Focus on oxidative stress and endothelial progenitor cells. Endocrine 2015, 50, 537-567. [CrossRef] [PubMed]
10. Lin, K. Y.; Ito, A.; Asagami, T.; Tsao, P. S.; Adimoolam, S.; Kimoto, M.; Tsuji, H.; Reaven, G. M.; Cooke, J. P. Impaired nitric oxide synthase pathway in diabetes mellitus: Role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002, 106, 987-992. [CrossRef] [PubMed]
11. Li, H.; Förstermann, U. Nitric oxide in the pathogenesis of vascular disease. J. Pathol. 2000, 190, 244-254. [CrossRef]
12. Camont, L.; Collin, F.; Marchetti, C.; Jore, D.; Gardes-Albert, M.; Bonnefont-Rousselot, D. Liquid chromatographic/electrospray ionization mass spectrometric identification of the oxidation end-products of trans-resveratrol in aqueous solutions. Rapid Commun. Mass Spectrom. 2010, 24, 634-642. [CrossRef] [PubMed]
13. Camont, L.; Collin, F.; Couturier, M.; Thérond, P.; Jore, D.; Gardès-Albert, M.; Bonnefont-Rousselot, D. Radical-induced oxidation of trans-resveratrol. Biochimie 2012, 94, 741-747. [CrossRef] [PubMed]
14. Rhayem, Y.; Thérond, P.; Camont, L.; Couturier, M.; Beaudeux, J. L.; Legrand, A.; Jore, D.; Gardés-Albert, M.; Bonnefont-Rousselot, D. Chain-breaking activity of resveratrol and piceatannol in a linoleate micellar model. Chem. Phys. Lipids 2008, 155, 48-56. [CrossRef] [PubMed]
15. Scalera, F.; Kielstein, J. T.; Martens-Lobenhoffer, J.; Postel, S. C.; Täger, M.; Bode-Böger, S. M. Erythropoietin increases asymmetric dimethylarginine in endothelial cells: Role of dimethylarginine dimethylaminohydrolase. J. Am. Soc. Nephrol. 2005, 16, 892-898. [CrossRef] [PubMed]
16. Frombaum, M.; le Clanche, S.; Bonnefont-Rousselot, D.; Borderie, D. Antioxidant effects of resveratrol and other stilbene derivatives on oxidative stress and NO bioavailability: Potential benefits to cardiovascular diseases. Biochimie 2012, 94, 269-276. [CrossRef] [PubMed]
17. Frombaum, M.; Thérond, P.; Djelidi, R.; Beaudeux, J. L.; Bonnefont-Rousselot, D.; Borderie, D. Piceatannol is more effective than resveratrol in restoring endothelial cell dimethylargininedimethylaminohydrolase expression and activity after high-glucose oxidative stress. Free Radic. Res. 2011, 45, 293-302. [CrossRef] [PubMed]
18. Bivalacqua, T. J.; Hellstrom, W. J.; Kadowitz, P. J.; Champion, H. C. Increased expression of arginase II in human diabetic corpus cavernosum: In diabetic-associated erectile dysfunction. Biochem. Biophys. Res. Commun. 2001, 283, 923-927. [CrossRef] [PubMed]
19. White, A. R.; Ryoo, S.; Li, D.; Champion, H. C.; Steppan, J.; Wang, D.; Nyhan, D.; Shoukas, A. A.; Hare, J. M.; Berkowitz, D. E. Knockdown of arginase I restores NO signaling in the vasculature of old rats. Hypertension 2006, 47, 245-251. [CrossRef] [PubMed]
20. Hong, L.; Fast, W. Inhibition of human dimethylarginine dimethylaminohydrolase-1 by S-nitroso-L-homocysteine and hydrogen peroxide. Analysis, quantification, and implications for hyperhomocysteinemia. J. Biol. Chem. 2007, 282, 34684-34692. [CrossRef] [PubMed]
21. Yuan, Q.; Peng, J.; Liu, S. Y.; Wang, C. J.; Xiang, D. X.; Xiong, X. M.; Hu, C. P.; Li, Y. J. Inhibitory effect of resveratrol derivative BTM-0512 on high glucose-induced cell senescence involves dimethylaminohydrolase/asymmetric dimethylarginine pathway. Clin. Exp. Pharmacol. Physiol. 2010, 37, 630-635. [CrossRef] [PubMed]
22. Dolinsky, V. W.; Dyck, J. R. Calorie restriction and resveratrol in cardiovascular health and disease. Biochim. Biophys. Acta 2011, 1812, 1477-1489. [CrossRef] [PubMed]
23. Li, H.; Xia, N.; Förstermann, U. Cardiovascular effects and molecular targets of resveratrol. Nitric Oxide 2012, 26, 102-110. [CrossRef] [PubMed]
24. Fichtlscherer, S.; Zeiher, A. M.; Dimmeler, S. Circulating microRNAs: Biomarkers or mediators of cardiovascular diseases? Arterioscler. Thromb. Vasc. Biol. 2011, 31, 2383-2390. [CrossRef] [PubMed]
25. Mukhopadhyay, P.; Pacher, P.; Das, D. K. MicroRNA signatures of resveratrol in the ischemic heart. Ann. N. Y. Acad. Sci. 2011, 1215, 109-116. [CrossRef] [PubMed]
26. Tomé-Carneiro, J.; Larrosa, M.; González-Sarrías, A.; Tomás-Barberán, F. A.; García-Conesa, M. T.; Espín, J. C. Resveratrol and clinical trials: The crossroad from in vitro studies to human evidence. Curr. Pharm. Des. 2013, 19, 6064-6093. [CrossRef] [PubMed]
27. Glass, C. K.; Witztum, J. L. Atherosclerosis. The road ahead. Cell 2001, 104, 503-516. [CrossRef]
28. Göçmen, A. Y.; Burgucu, D.; Gümüşlü, S. Effect of resveratrol on platelet activation in hypercholesterolemic rats: CD40-CD40L system as a potential target. Appl. Physiol. Nutr. Metab. 2011, 36, 323-330. [CrossRef] [PubMed]
29. Cho, I. J.; Ahn, J. Y.; Kim, S.; Choi, M. S.; Ha, T. Y. Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters. Biochem. Biophys. Res. Commun. 2008, 367, 190-194. [CrossRef] [PubMed]
30. Yashiro, T.; Nanmoku, M.; Shimizu, M.; Inoue, J.; Sato, R. Resveratrol increases the expression and activity of the low density lipoprotein receptor in hepatocytes by the proteolytic activation of the sterol regulatory element-binding proteins. Atherosclerosis 2012, 220, 369-374. [CrossRef] [PubMed]
31. Witztum, J. L.; Steinberg, D. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Investig. 1991, 88, 1785-1792. [CrossRef] [PubMed]
32. Berrougui, H.; Grenier, G.; Loued, S.; Drouin, G.; Khalil, A. A new insight into resveratrol as an atheroprotective compound: Inhibition of lipid peroxidation and enhancement of cholesterol efflux. Atherosclerosis 2009, 207, 420-427. [CrossRef] [PubMed]
33. Ramprasath, V. R.; Jones, P. J. Anti-atherogenic effects of resveratrol. Eur. J. Clin. Nutr. 2010, 64, 660-668. [CrossRef] [PubMed]
34. Lin, Y. C.; Chen, L. H.; Varadharajan, T.; Tsai, M. J.; Chia, Y. C.; Yuan, T. C.; Sung, P. J.; Weng, C. F. Resveratrol inhibits glucose-induced migration of vascular smooth muscle cells mediated by focal adhesion kinase. Mol. Nutr. Food Res. 2014, 58, 1389-1401. [CrossRef] [PubMed]
35. Haskó, G.; Pacher, P. Endothelial Nrf2 activation: A new target for resveratrol? Am. J. Physiol. Heart Circ. Physiol. 2010, 299, H10-H12. [CrossRef] [PubMed]
36. Deng, Y. H.; Alex, D.; Huang, H. Q.; Wang, N.; Yu, N.; Wang, Y. T.; Leung, G. P.; Lee, S. M. Inhibition of TNF-α-mediated endothelial cell-monocyte cell adhesion and adhesion molecules expression by the resveratrol derivative, trans-3, 5, 4ʹ-trimethoxystilbene. Phytother. Res. 2011, 25, 451-457. [CrossRef] [PubMed]
37. Park, D. W.; Baek, K.; Kim, J. R.; Lee, J. J.; Ryu, S. H.; Chin, B. R.; Baek, S. H. Resveratrol inhibits foam cell formation via NADPH oxidase 1-mediated reactive oxygen species and monocyte chemotactic protein-1. Exp. Mol. Med. 2009, 41, 171-179. [CrossRef] [PubMed]
38. Latruffe, N.; Lançon, A.; Frazzi, R.; Aires, V.; Delmas, D.; Michaille, J. J.; Djouadi, F.; Bastin, J.; Cherkaoui-Malki, M. Exploring new ways of regulation by resveratrol involving miRNAs, with emphasis on inflammation. Ann. N. Y. Acad. Sci. 2015, 1348, 97-106. [CrossRef] [PubMed]
39. Hao, E.; Lang, F.; Chen, Y.; Zhang, H.; Cong, X.; Shen, X.; Su, G. Resveratrol alleviates endotoxin-induced myocardial toxicity via the Nrf2 transcription factor. PLoS ONE 2013, 8, e69452. [CrossRef] [PubMed]
40. El-Mowafy, A. M.; Alkhalaf, M.; El-Kashef, H. A. Resveratrol reverses hydrogen peroxide-induced proliferative effects in human coronary smooth muscle cells: A novel signaling mechanism. Arch. Med. Res. 2008, 39, 155-161. [CrossRef] [PubMed]
41. Sahebkar, A. Effects of resveratrol supplementation on plasma lipids: A systematic review and meta-analysis of randomized controlled trials. Nutr. Rev. 2013, 71, 822-835. [CrossRef] [PubMed]
42. Bhatt, J. K.; Thomas, S.; Nanjan, M. J. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr. Res. 2012, 32, 537-541. [CrossRef] [PubMed]
43. Timmers, S.; Konings, E.; Bilet, L.; Houtkooper, R. H.; van de Weijer, T.; Goossens, G. H.; Hoeks, J.; van der Krieken, S.; Ryu, D.; Kersten, S.; et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011, 14, 612-622. [CrossRef] [PubMed]
44. Bo, S.; Ciccone, G.; Castiglione, A.; Gambino, R.; de Michieli, F.; Villois, P.; Durazzo, M.; Cavallo-Perin, P.; Cassader, M. Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. Curr. Med. Chem. 2013, 20, 1323-1231. [CrossRef] [PubMed]
45. Tomé-Carneiro, J.; Gonzálvez, M.; Larrosa, M.; García-Almagro, F. J.; Avilés-Plaza, F.; Parra, S.; Yáñez-Gascón, M. J.; Ruiz-Ros, J. A.; García-Conesa, M. T.; Tomás-Barberán, F. A.; et al. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: A triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Mol. Nutr. Food Res. 2012, 56, 810-821. [CrossRef] [PubMed]
46. Smulyan, H.; Mookherjee, S.; Safar, M. E. The two faces of hypertension: Role of aortic stiffness. J. Am. Soc. Hypertens. 2016, 10, 175-183. [CrossRef] [PubMed]
47. Rivera, L.; Morón, R.; Zarzuelo, A.; Galisteo, M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem. Pharmacol. 2009, 77, 1053-1063. [CrossRef] [PubMed]
48. Dolinsky, V. W.; Chakrabarti, S.; Pereira, T. J.; Oka, T.; Levasseur, J.; Beker, D.; Zordoky, B. N.; Morton, J. S.; Nagendran, J.; Lopaschuk, G. D.; et al. Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. Biochim. Biophys. Acta 2013, 1832, 1723-1733. [CrossRef] [PubMed]
49. Chan, V.; Fenning, A.; Iyer, A.; Hoey, A.; Brown, L. Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats. Curr. Pharm. Biotechnol. 2011, 12, 429-436. [CrossRef] [PubMed]
50. Rimbaud, S.; Ruiz, M.; Piquereau, J.; Mateo, P.; Fortin, D.; Veksler, V.; Garnier, A.; Ventura-Clapier, R. Resveratrol improves survival, hemodynamics and energetics in a rat model of hypertension leading to heart failure. PLoS ONE 2011, 6, e26391. [CrossRef] [PubMed]
51. Thandapilly, S. J.; Louis, X. L.; Behbahani, J.; Movahed, A.; Yu, L.; Fandrich, R.; Zhang, S.; Kardami, E.; Anderson, H. D.; Netticadan, T. Reduced hemodynamic load aids low-dose resveratrol in reversing cardiovascular defects in hypertensive rats. Hypertens. Res. 2013, 36, 866-872. [CrossRef] [PubMed]
52. Gordish, K. L.; Beierwaltes, W. H. Resveratrol induces acute endothelium-dependent renal vasodilation mediated through nitric oxide and reactive oxygen species scavenging. Am. J. Physiol. Ren. Physiol. 2014, 306, F542-F550. [CrossRef] [PubMed]
53. Arunachalam, G.; Yao, H.; Sundar, I. K.; Caito, S.; Rahman, I. SIRT1 regulates oxidant-and cigarette smoke-induced eNOS acetylation in endothelial cells: Role of resveratrol. Biochem. Biophys. Res. Commun. 2010, 393, 66-72. [CrossRef] [PubMed]
54. Soylemez, S.; Sepici, A.; Akar, F. Resveratrol supplementation gender independently improves endothelial reactivity and suppresses superoxide production in healthy rats. Cardiovasc. Drugs Ther. 2009, 23, 449-458. [CrossRef] [PubMed]
55. Rush, J. W.; Quadrilatero, J.; Levy, A. S.; Ford, R. J. Chronic resveratrol enhances endothelium-dependent relaxation but does not alter eNOS levels in aorta of spontaneously hypertensive rats. Exp. Biol. Med. (Maywood) 2007, 232, 814-822. [PubMed]
56. Cao, X.; Luo, T.; Luo, X.; Tang, Z. Resveratrol prevents AngII-induced hypertension via AMPK activation and RhoA/ROCK suppression in mice. Hypertens. Res. 2014, 37, 803-810. [CrossRef] [PubMed]
57. Liu, Y.; Ma, W.; Zhang, P.; He, S.; Huang, D. Effect of resveratrol on blood pressure: A meta-analysis of randomized controlled trials. Clin. Nutr. 2015, 34, 27-34. [CrossRef] [PubMed]
58. Carrizzo, A.; Puca, A.; Damato, A.; Marino, M.; Franco, E.; Pompeo, F.; Traficante, A.; Civitillo, F.; Santini, L.; Trimarco, V.; et al. Resveratrol improves vascular function in patients with hypertension and dyslipidemia by modulating NO metabolism. Hypertension 2013, 62, 359-366. [CrossRef] [PubMed]
59. Clark, D.; Tuor, U. I.; Thompson, R.; Institoris, A.; Kulynych, A.; Zhang, X.; Kinniburgh, D. W.; Bari, F.; Busija, D. W.; Barber, P. A. Protection against recurrent stroke with resveratrol: Endothelial protection. PLoS ONE 2012, 7, e47792. [CrossRef] [PubMed]
60. Huang, S. S.; Tsai, M. C.; Chih, C. L.; Hung, L. M.; Tsai, S. K. Resveratrol reduction of infarct size in Long-Evans rats subjected to focal cerebral ischemia. Life Sci. 2001, 69, 1057-1065. [CrossRef]
61. Arrick, D. M.; Sun, H.; Patel, K. P.; Mayhan, W. G. Chronic resveratrol treatment restores vascular responsiveness of cerebral arterioles in type 1 diabetic rats. Am. J. Physiol. Heart Circ. Physiol. 2011, 301, H696-H703. [CrossRef] [PubMed]
62. Singh, N.; Agrawal, M.; Doré, S. Neuroprotective properties and mechanisms of resveratrol in in vitro and in vivo experimental cerebral stroke models. ACS Chem. Neurosci. 2013, 4, 1151-1162. [CrossRef] [PubMed]
63. Wan, D.; Zhou, Y.; Wang, K.; Hou, Y.; Hou, R.; Ye, X. Resveratrol provides neuroprotection by inhibiting phosphodiesterases and regulating the cAMP/AMPK/SIRT1 pathway after stroke in rats. Brain Res. Bull. 2016, 121, 255-262. [CrossRef] [PubMed]
64. Kennedy, D. O.; Wightman, E. L.; Reay, J. L.; Lietz, G.; Okello, E. J.; Wilde, A.; Haskell, C. F. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: A double-blind, placebo-controlled, crossover investigation. Am. J. Clin. Nutr. 2010, 91, 1590-1597. [CrossRef] [PubMed]
65. Wightman, E. L.; Reay, J. L.; Haskell, C. F.; Williamson, G.; Dew, T. P.; Kennedy, D. O. Effects of resveratrol alone or in combination with piperine on cerebral blood flow parameters and cognitive performance in human subjects: A randomised, double-blind, placebo-controlled, cross-over investigation. Br. J. Nutr. 2014, 112, 203-213. [CrossRef] [PubMed]
66. Evans, H. M.; Howe, P. R.; Wong, R. H. Clinical evaluation of effects of chronic resveratrol supplementation on cerebrovascular function, cognition, mood, physical function and general well-being in postmenopausal women-rationale and study design. Nutrients 2016, 8. [CrossRef] [PubMed]
67. Raj, P.; Louis, X. L.; Thandapilly, S. J.; Movahed, A.; Zieroth, S.; Netticadan, T. Potential of resveratrol in the treatment of heart failure. Life Sci. 2014, 95, 63-71. [CrossRef] [PubMed]
68. Hung, L. M.; Su, M. J.; Chen, J. K. Resveratrol protects myocardial ischemia-reperfusion injury through both NO-dependent and NO-independent mechanisms. Free Radic. Biol. Med. 2004, 36, 774-781. [CrossRef] [PubMed]
69. Shen, M.; Jia, G. L.; Wang, Y. M.; Ma, H. Cardioprotective effect of resvaratrol pretreatment on myocardial ischemia-reperfusion induced injury in rats. Vasc. Pharmacol. 2006, 45, 122-126. [CrossRef] [PubMed]
70. Shalwala, M.; Zhu, S. G.; Das, A.; Salloum, F. N.; Xi, L.; Kukreja, R. C. Sirtuin 1 (SIRT1) activation mediates sildenafil induced delayed cardioprotection against ischemia-reperfusion injury in mice. PLoS ONE 2014, 9, e86977. [CrossRef] [PubMed]
71. Das, S.; Cordis, G. A.; Maulik, N.; Das, D. K. Pharmacological preconditioning with resveratrol: Role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation. Am. J. Physiol. Heart Circ. Physiol. 2005, 288, H328-H335. [CrossRef] [PubMed]
72. Kaga, S.; Zhan, L.; Matsumoto, M.; Maulik, N. Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. J. Mol. Cell. Cardiol. 2005, 39, 813-822. [CrossRef] [PubMed]
73. Fukuda, S.; Kaga, S.; Zhan, L.; Bagchi, D.; Das, D. K.; Bertelli, A.; Maulik, N. Resveratrol ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1. Cell Biochem. Biophys. 2006, 44, 43-49. [CrossRef]
74. Chen, Y. R.; Yi, F. F.; Li, X. Y.; Wang, C. Y.; Chen, L.; Yang, X. C.; Su, P. X.; Cai, J. Resveratrol attenuates ventricular arrhythmias and improves the long-term survival in rats with myocardial infarction. Cardiovasc. Drugs Ther. 2008, 22, 479-485. [CrossRef] [PubMed]
75. Robich, M. P.; Osipov, R. M.; Chu, L. M.; Han, Y.; Feng, J.; Nezafat, R.; Clements, R. T.; Manning, W. J.; Sellke, F. W. Resveratrol modifies risk factors for coronary artery disease in swine with metabolic syndrome and myocardial ischemia. Eur. J. Pharmacol. 2011, 664, 45-53. [CrossRef] [PubMed]
76. Gurusamy, N.; Lekli, I.; Mukherjee, S.; Ray, D.; Ahsan, M. K.; Gherghiceanu, M.; Popescu, L. M.; Das, D. K. Cardioprotection by resveratrol: A novel mechanism via autophagy involving the mTORC2 pathway. Cardiovasc. Res. 2010, 86, 103-112. [CrossRef] [PubMed]
77. Xuan, W.; Wu, B.; Chen, C.; Chen, B.; Zhang, W.; Xu, D.; Bin, J.; Liao, Y. Resveratrol improves myocardial ischemia and ischemic heart failure in mice by antagonizing the detrimental effects of fractalkine. Crit. Care Med. 2012, 40, 3026-3033. [CrossRef] [PubMed]
78. Gu, X. S.; Wang, Z. B.; Ye, Z.; Lei, J. P.; Li, L.; Su, D. F.; Zheng, X. Resveratrol, an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure. Genet. Mol. Res. 2014, 13, 323-335. [CrossRef] [PubMed]
79. Kanamori, H.; Takemura, G.; Goto, K.; Tsujimoto, A.; Ogino, A.; Takeyama, T.; Kawaguchi, T.; Watanabe, T.; Morishita, K.; Kawasaki, M.; et al. Resveratrol reverses remodeling in hearts with large, old myocardial infarctions through enhanced autophagy-activating AMP kinase pathway. Am. J. Pathol. 2013, 182, 701-713. [CrossRef] [PubMed]
80. Sabe, A. A.; Elmadhun, N. Y.; Dalal, R. S.; Robich, M. P.; Sellke, F. W. Resveratrol regulates autophagy signaling in chronically ischemic myocardium. J. Thorac. Cardiovasc. Surg. 2014, 147, 792-798. [CrossRef] [PubMed]
81. Shen, M.; Wu, R. X.; Zhao, L.; Li, J.; Guo, H. T.; Fan, R.; Cui, Y.; Wang, Y. M.; Yue, S. Q.; Pei, J. M. Resveratrol attenuates ischemia/reperfusion injury in neonatal cardiomyocytes and its underlying mechanism. PLoS ONE 2012, 7, e51223. [CrossRef] [PubMed]
82. Sabe, A. A.; Sadek, A. A.; Elmadhun, N. Y.; Dalal, R. S.; Robich, M. P.; Bianchi, C.; Sellke, F. W. Investigating the effects of resveratrol on chronically ischemic myocardium in a swine model of metabolic syndrome: A proteomics analysis. J. Med. Food 2015, 18, 60-66. [CrossRef] [PubMed]
83. Dong, W.; Yang, R.; Yang, J.; Yang, J.; Ding, J.; Wu, H.; Zhang, J. Resveratrol pretreatment protects rat hearts from ischemia/reperfusion injury partly via a NALP3 inflammasome pathway. Int. J. Clin. Exp. Pathol. 2015, 8, 8731-8741. [PubMed]
84. Mukhopadhyay, P.; Mukherjee, S.; Ahsan, K.; Bagchi, A.; Pacher, P.; Das, D. K. Restoration of altered microRNA expression in the ischemic heart with resveratrol. PLoS ONE 2010, 5, e15705. [CrossRef] [PubMed]
85. Thum, T.; Gross, C.; Fiedler, J.; Fischer, T.; Kissler, S.; Bussen, M.; Galuppo, P.; Just, S.; Rottbauer, W.; Frantz, S.; et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signaling in fibroblasts. Nature 2008, 456, 980-984. [CrossRef] [PubMed]
86. Roy, S.; Khanna, S.; Hussain, S. R.; Biswas, S.; Azad, A.; Rink, C.; Gnyawali, S.; Shilo, S.; Nuovo, G. J.; Sen, C. K. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc. Res. 2009, 82, 21-29. [CrossRef] [PubMed]
87. Cascio, S.; D'Andrea, A.; Ferla, R.; Surmacz, E.; Gulotta, E.; Amodeo, V.; Bazan, V.; Gebbia, N.; Russo, A. miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells. J. Cell. Physiol. 2010, 224, 242-249. [PubMed]
88. Guttilla, I. K.; White, B. A. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J. Biol. Chem. 2009, 284, 23204-23216. [CrossRef] [PubMed]
89. Saunders, L. R.; Sharma, A. D.; Tawney, J.; Nakagawa, M.; Okita, K.; Yamanaka, S.; Willenbring, H.; Verdin, E. miRNAs regulate SIRT1 expression during mouse embryonic stem cell differentiation and in adult mouse tissues. Aging (Albany NY) 2010, 2, 415-431. [CrossRef] [PubMed]
90. Van Rooij, E.; Sutherland, L. B.; Thatcher, J. E.; DiMaio, J. M.; Naseem, R. H.; Marshall, W. S.; Hill, J. A.; Olson, E. N. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl. Acad. Sci. USA 2008, 105, 13027-13032. [CrossRef] [PubMed]
91. Yin, K.; Zhao, L.; Feng, D.; Ma, W.; Liu, Y.; Wang, Y.; Liang, J.; Yang, F.; Bi, C.; Chen, H.; et al. Resveratrol attenuated low ambient temperature-induced myocardial hypertrophy via inhibiting cardiomyocyte apoptosis. Cell. Physiol. Biochem. 2015, 35, 2451-2462. [CrossRef] [PubMed]
92. Tomé-Carneiro, J.; Gonzálvez, M.; Larrosa, M.; Yáñez-Gascón, M. J.; García-Almagro, F. J.; Ruiz-Ros, J. A.; Tomás-Barberán, F. A.; García-Conesa, M. T.; Espín, J. C. Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: A triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovasc. Drugs Ther. 2013, 27, 37-48. [CrossRef] [PubMed]
93. Magyar, K.; Halmosi, R.; Palfi, A.; Feher, G.; Czopf, L.; Fulop, A.; Battyany, I.; Sumegi, B.; Toth, K.; Szabados, E. Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. Clin. Hemorheol. Microcirc. 2012, 50, 179-187. [PubMed]
94. Walle, T.; Hsieh, F.; DeLegge, M. H.; Oatis, J. E.; Walle, U. K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 2004, 32, 1377-1382. [CrossRef] [PubMed]
95. Militaru, C.; Donoiu, I.; Craciun, A.; Scorei, I. D.; Bulearca, A. M.; Scorei, R. I. Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: Effects on lipid profiles, inflammation markers, and quality of life. Nutrition 2013, 29, 178-183. [CrossRef] [PubMed]
96. Gupta, P. K.; DiPette, D. J.; Supowit, S. C. Protective effect of resveratrol against pressure overload-induced heart failure. Food Sci. Nutr. 2014, 2, 218-229. [CrossRef] [PubMed]
97. Tanno, M.; Kuno, A.; Yano, T.; Miura, T.; Hisahara, S.; Ishikawa, S.; Shimamoto, K.; Horio, Y. Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J. Biol. Chem. 2010, 285, 8375-8382. [CrossRef] [PubMed]
98. Chan, A. Y.; Dolinsky, V. W.; Soltys, C. L.; Viollet, B.; Baksh, S.; Light, P. E.; Dyck, J. R. Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J. Biol. Chem. 2008, 283, 24194-24201. [CrossRef] [PubMed]
99. Sulaiman, M.; Matta, M. J.; Sunderesan, N. R.; Gupta, M. P.; Periasamy, M.; Gupta, M. Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 2010, 298, H833-H843. [CrossRef] [PubMed]
100. Dolinsky, V. W.; Soltys, C. L.; Rogan, K. J.; Chan, A. Y.; Nagendran, J.; Wang, S.; Dyck, J. R. Resveratrol prevents pathological but not physiological cardiac hypertrophy. J. Mol. Med. (Berl.) 2015, 93, 413-425. [CrossRef] [PubMed]
101. Azorín-Ortuño, M.; Yáñez-Gascón, M. J.; Vallejo, F.; Pallarés, F. J.; Larrosa, M.; Lucas, R.; Morales, J. C.; Tomás-Barberán, F. A.; García-Conesa, M. T.; Espín, J. C. Metabolites and tissue distribution of resveratrol in the pig. Mol. Nutr. Food Res. 2011, 55, 1154-1168. [CrossRef] [PubMed]
102. Bresciani, L.; Calani, L.; Bocchi, L.; Delucchi, F.; Savi, M.; Ray, S.; Brighenti, F.; Stilli, D.; del Rio, D. Bioaccumulation of resveratrol metabolites in myocardial tissue is dose-time dependent and related to cardiac hemodynamics in diabetic rats. Nutr. Metab. Cardiovasc. Dis. 2014, 24, 408-415. [CrossRef] [PubMed]
103. Brantley, S. J.; Argikar, A. A.; Lin, Y. S.; Nagar, S.; Paine, M. F. Herb-drug interactions: Challenges and opportunities for improved predictions. Drug Metab. Dispos. 2014, 42, 301-317. [CrossRef] [PubMed]
104. Cottart, C. H.; Nivet-Antoine, V.; Laguillier-Morizot, C.; Beaudeux, J. L. Resveratrol bioavailability and toxicity in humans. Mol. Nutr. Food Res. 2010, 54, 7-16. [CrossRef] [PubMed]
105. Goldberg, D. M.; Yan, J.; Soleas, G. J. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin. Biochem. 2003, 36, 79-87. [CrossRef]
106. Calamini, B.; Ratia, K.; Malkowski, M. G.; Cuendet, M.; Pezzuto, J. M.; Santarsiero, B. D.; Mesecar, A. D. Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem. J. 2010, 429, 273-282. [CrossRef] [PubMed]
107. Boocock, D. J.; Faust, G. E.; Patel, K. R.; Schinas, A. M.; Brown, V. A.; Ducharme, M. P.; Booth, T. D.; Crowell, J. A.; Perloff, M.; Gescher, A. J.; et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomark. Prev. 2007, 16, 1246-1252. [CrossRef] [PubMed]
108. Das, S.; Ng, K. Y. Impact of glutaraldehyde on in vivo colon-specific release of resveratrol from biodegradable pectin-based formulation. J. Pharm. Sci. 2010, 99, 4903-4916. [CrossRef] [PubMed]
109. Lu, X.; Ji, C.; Xu, H.; Li, X.; Ding, H.; Ye, M.; Zhu, Z.; Ding, D.; Jiang, X.; Ding, X.; et al. Resveratrol-loaded polymeric micelles protect cells from Abeta-induced oxidative stress. Int. J. Pharm. 2009, 375, 89-96. [CrossRef] [PubMed]
110. Amri, A.; le Clanche, S.; Thérond, P.; Bonnefont-Rousselot, D.; Borderie, D.; Lai-Kuen, R.; Chaumeil, J. C.; Sfar, S.; Charrueau, C. Resveratrol self-emulsifying system increases the uptake by endothelial cells and improves protection against oxidative stress-mediated death. Eur. J. Pharm. Biopharm. 2014, 86, 418-426. [CrossRef] [PubMed]
111. Neves, A. R.; Martins, S.; Segundo, M. A.; Reis, S. Nanoscale delivery of resveratrol towards enhancement of supplements and nutraceuticals. Nutrients 2016, 8. [CrossRef]
112. Diaz-Gerevini, G. T.; Repossi, G.; Dain, A.; Tarres, M. C.; Das, U. N.; Eynard, A. R. Beneficial action of resveratrol: How and why? Nutrition 2016, 32, 174-178. [CrossRef] [PubMed]
113. Penalva, R.; Esparza, I.; Larraneta, E.; González-Navarro, C. J.; Gamazo, C.; Irache, J. M. Zein-based nanoparticles improve the oral bioavailability of resveratrol and its anti-inflammatory effects in a mouse model of endotoxic shock. J. Agric. Food Chem. 2015, 63, 5603-5611. [CrossRef] [PubMed]
114. Da Rocha Lindner, G.; Santos, D. B.; Colle, D.; Moreira, E. L. G.; Prediger, R. D.; Farina, M.; Khalil, N. M.; Mainardes, R. M. Improved neuroprotective effects of resveratrol-loadedpolysorbate 80-coated poly (lactide) nanoparticles in MPTP-induced parkinsonism. Nanomedicine (Lond.) 2015, 10, 1127-1138. [CrossRef] [PubMed]
115. Gepner, Y.; Golan, R.; Harman-Boehm, I.; Henkin, Y.; Schwarzfuchs, D.; Shelef, I.; Durst, R.; Kovsan, J.; Bolotin, A.; Leitersdorf, E.; et al. Effects of initiating moderate alcohol intake on cardiometabolic risk in adults with type 2 diabetes: A 2-year randomized, controlled trial. Ann. Intern. Med. 2015, 163, 569-579. [CrossRef] [PubMed]
116. Juhasz, B.; Mukherjee, S.; Das, D. K. Hormetic response of resveratrol against cardioprotection. Exp. Clin. Cardiol. 2010, 15, e134-e138. [PubMed]
117. Kucinska, M.; Piotrowska, H.; Luczak, M. W.; Mikula-Pietrasik, J.; Ksiazek, K.; Wozniak, M.; Wierzchowski, M.; Dudka, J.; Jäger, W.; Murias, M. Effects of hydroxylated resveratrol analogs on oxidative stress and cancer cells death in human acute T cell leukemia cell line: Prooxidativepotential of hydroxylated resveratrol analogs. Chem. Biol. Interact. 2014, 209, 96-110. [CrossRef] [PubMed]
118. Chang, T. K.; Chen, J.; Lee, W. B. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: Evidence for mechanism-based inactivation of CYP1A2. J. Pharmacol. Exp. Ther. 2001, 299, 874-882. [PubMed]
119. Chow, H. H.; Garland, L. L.; Hsu, C. H.; Vining, D. R.; Chew, W. M.; Miller, J. A.; Perloff, M.; Crowell, J. A.; Alberts, D. S. Resveratrol modulates drug-and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev. Res. (Phila) 2010, 3, 1168-1175. [CrossRef] [PubMed]
120. Iwuchukwu, O. F.; Tallarida, R. J.; Nagar, S. Resveratrol in combination with other dietary polyphenols concomitantly enhances antiproliferation and UGT1A1 induction in Caco-2 cells. Life Sci. 2011, 88, 1047-1054. [CrossRef] [PubMed]
121. Detampel, P.; Beck, M.; Krähenbühl, S.; Huwyler, J. Drug interaction potential of resveratrol. Drug Metab. Rev. 2012, 44, 253-265. [CrossRef] [PubMed]
122. Yu, C.; Shin, Y. G.; Kosmeder, J. W.; Pezzuto, J. M.; van Breemen, R. B. Liquid chromatography/tandemmass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun. Mass Spectrom. 2003, 17, 307-313. [CrossRef] [PubMed]
123. Ogu, C. C.; Maxa, J. L. Drug interactions due to cytochrome P450. Proceeding (Bayl. Univ. Med. Cent.) 2000, 13, 421-423.
124. Visioli, F. The resveratrol fiasco. Pharmacol. Res. 2014, 90, 87. [CrossRef] [PubMed]
125. Tomé-Carneiro, J.; Larrosa, M.; Yáñez-Gascón, M. J.; Dávalos, A.; Gil-Zamorano, J.; Gonzálvez, M.; García-Almagro, F. J.; Ros, J. A. R.; Tomás-Barberán, F. A.; Espín, J. C.; et al. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol. Res. 2013, 72, 69-82. [CrossRef] [PubMed]
126. Tang, P. C.-T.; Ng, Y.-F.; Ho, S.; Gyda, M.; Chan, S.-W. Resveratrol and cardiovascular health-Promising therapeutic or hopeless illusion? Pharmacol. Res. 2014, 90, 88-115. [CrossRef] [PubMed]
127. Cruz, M. N.; Luksha, L.; Logman, H.; Poston, L.; Agewall, S.; Kublickiene, K. Acute responses to phytoestrogens in small arteries from men with coronary heart disease. Am. J. Physiol. Heart Circ. Physiol. 2006, 290, H1969-H1975. [CrossRef] [PubMed]
128. Rakici, O.; Kiziltepe, U.; Coskun, B.; Aslamaci, S.; Akar, F. Effects of resveratrol on vascular tone and endothelial function of human saphenous vein and internal mammary artery. Int. J. Cardiol. 2005, 105, 209-215. [CrossRef] [PubMed]
129. Amadio, P.; Baldassarre, D.; Tarantino, E.; Zacchi, E.; Gianellini, S.; Squellerio, I.; Amato, M.; Weksler, B. B.; Tremoli, E.; Barbieri, S. S. Production of prostaglandin E2 induced by cigarette smoke modulates tissue factor expression and activity in endothelial cells. FASEB J. 2015, 29, 4001-4010. [CrossRef] [PubMed]
130. Thushara, R. M.; Hemshekhar, M.; Paul, M.; Sundaram, M. S.; Shankar, R. L.; Kemparaju, K.; Girish, K. S. Crocin prevents sesamol-induced oxidative stress and apoptosis in human platelets. J. Thromb. Thrombolysis 2014, 38, 321-330. [CrossRef] [PubMed]
131. Zamora-Ros, R.; Urpí-Sardà, M.; Lamuela-Raventós, R. M.; Estruch, R.; Vázquez-Agell, M.; Serrano-Martínez, M.; Jaeger, W.; Andres-Lacueva, C. Diagnostic performance of urinary resveratrol metabolites as a biomarker of moderate wine consumption. Clin. Chem. 2006, 52, 1373-1380. [CrossRef] [PubMed]
132. Faghihzadeh, F.; Adibi, P.; Hekmatdoost, A. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: Arandomised, double-blind, placebo-controlled study. Br. J. Nutr. 2015, 114, 796-803. [CrossRef] [PubMed]
133. Van der Made, S. M.; Plat, J.; Mensink, R. P. Resveratrol does not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects: A randomized, placebo-controlled crossover trial. PLoS ONE 2015, 10, e0118393.
134. Semba, R. D.; Ferrucci, L.; Bartali, B.; Urpí-Sarda, M.; Zamora-Ros, R.; Sun, K.; Cherubini, A.; Bandinelli, S.; Andres-Lacueva, C. Resveratrol levels and all-cause mortality in older community-dwelling adults. JAMA Intern. Med. 2014, 174, 1077-1084. [CrossRef] [PubMed]
135. Soare, A.; Weiss, E. P.; Holloszy, J. O.; Fontana, L. Multiple dietary supplements do not affect metabolic and cardio-vascular health. Aging (Albany NY) 2014, 6, 149-157. [CrossRef] [PubMed]
136. Huang, J. P.; Huang, S. S.; Deng, J. Y.; Chang, C. C.; Day, Y. J.; Hung, L. M. Insulin and resveratrol act synergistically, preventing cardiac dysfunction in diabetes, but the advantage of resveratrol in diabetics with acute heart attack is antagonized by insulin. Free Radic. Biol. Med. 2010, 49, 1710-1721. [CrossRef] [PubMed]
137. Zhang, H.; Morgan, B.; Potter, B. J.; Ma, L.; Dellsperger, K. C.; Ungvari, Z.; Zhang, C. Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress: In vivo demonstration with magnetic resonance imaging. Am. J. Physiol. Heart Circ. Physiol. 2010, 299, H985-H994. [CrossRef] [PubMed]
138. Barger, J. L.; Kayo, T.; Vann, J. M.; Arias, E. B.; Wang, J.; Hacker, T. A.; Wang, Y.; Raederstorff, D.; Morrow, J. D.; Leeuwenburgh, C.; et al. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS ONE 2008, 3, e2264. [CrossRef]
139. Dang, W. The controversial world of sirtuins. Drug Discov. Today Technol. 2014, 12, e9-e17. [CrossRef] [PubMed]
140. Pacholec, M.; Bleasdale, J. E.; Chrunyk, B.; Cunningham, D.; Flynn, D.; Garofalo, R. S.; Griffith, D.; Griffor, M.; Loulakis, P.; Pabst, B.; et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem. 2010, 285, 8340-8351. [CrossRef] [PubMed]
141. Fernandez-Marcos, P. J.; Auwerx, J. Regulation of PGC-1α, a nodal regulator of mitochondrial biogenesis. Am. J. Clin. Nutr. 2011, 93, 884S-890S. [CrossRef] [PubMed]
142. Csiszar, A.; Labinskyy, N.; Pinto, J. T.; Ballabh, P.; Zhang, H.; Losonczy, G.; Pearson, K.; de Cabo, R.; Pacher, P.; Zhang, C.; et al. Resveratrol induces mitochondrial biogenesis in endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2009, 297, H13-H20. [CrossRef] [PubMed]
143. Louis, X. L.; Thandapilly, S. J.; MohanKumar, S. K.; Yu, L.; Taylor, C. G.; Zahradka, P.; Netticadan, T. Treatment with low-dose resveratrol reverses cardiac impairment in obese prone but not in obese resistant rats. J. Nutr. Biochem. 2012, 23, 1163-1169. [CrossRef] [PubMed]
144. Qin, F.; Siwik, D. A.; Luptak, I.; Hou, X.; Wang, L.; Higuchi, A.; Weisbrod, R. M.; Ouchi, N.; Tu, V. H.; Calamaras, T. D.; et al. The polyphenols resveratrol and S17834 prevent the structural and functional sequelae of diet-induced metabolic heart disease in mice. Circulation 2012, 125, 1757-1764. [CrossRef] [PubMed]
145. Su, H. C.; Hung, L. M.; Chen, J. K. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am. J. Physiol. Endocrinol. Metab. 2006, 290, E1339-E1346. [CrossRef] [PubMed]
146. Bagul, P. K.; Middela, H.; Matapally, S.; Padiya, R.; Bastia, T.; Madhusudana, K.; Reddy, B. R.; Chakravarty, S.; Banerjee, S. K. Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats. Pharmacol. Res. 2012, 66, 260-268. [CrossRef] [PubMed]
147. Turan, B.; Tuncay, E.; Vassort, G. Resveratrol and diabetic cardiac function: Focus on recent in vitro and in vivo studies. J. Bioenerg. Biomembr. 2012, 44, 281-296. [CrossRef] [PubMed]
148. Liu, K.; Zhou, R.; Wang, B.; Mi, M. T. Effect of resveratrol on glucose control and insulin sensitivity: Ameta-analysis of 11 randomized controlled trials. Am. J. Clin. Nutr. 2014, 99, 1510-1519. [CrossRef] [PubMed]
149. Haohao, Z.; Guijun, Q.; Juan, Z.; Wen, K.; Lulu, C. Resveratrol improves high-fat diet induced insulin resistance by rebalancing subsarcolemmal mitochondrial oxidation and antioxidantion. J. Physiol. Biochem. 2015, 71, 121-131. [CrossRef] [PubMed]
150. Beaudoin, M. S.; Perry, C. G.; Arkell, A. M.; Chabowski, A.; Simpson, J. A.; Wright, D. C.; Holloway, G. P. Impairments in mitochondrial palmitoyl-CoA respiratory kinetics that precede development of diabetic cardiomyopathy are prevented by resveratrol in ZDF rats. J. Physiol. 2014, 592, 2519-2533. [CrossRef] [PubMed]
151. Hobbs, T.; Caso, R.; McMahon, D.; Nymark, M. A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: A pilot study. Altern. Ther. Health Med. 2014, 20, 18-23. [PubMed]
152. Micans, P. Aortic wave velocity: A noninvasive method to measure the stiffness of arteries and the clinical results of supplements that appear to improve arterial stiffness. Curr. Aging Sci. 2013, 6, 76-85. [CrossRef] [PubMed]
153. Popat, R.; Plesner, T.; Davies, F.; Cook, G.; Cook, M.; Elliott, P.; Jacobson, E.; Gumbleton, T.; Oakervee, H.; Cavenagh, J. A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. Br. J. Haematol. 2013, 160, 714-717. [CrossRef] [PubMed]
154. Agarwal, B.; Campen, M. J.; Channell, M. M.; Wherry, S. J.; Varamini, B.; Davis, J. G.; Baur, J. A.; Smoliga, J. M. Resveratrol for primary prevention of atherosclerosis: Clinical trial evidence for improved gene expression in vascular endothelium. Int. J. Cardiol. 2013, 166, 246-248. [CrossRef] [PubMed]
155. Tomé-Carneiro, J.; Gonzálvez, M.; Larrosa, M.; Yáñez-Gascón, M. J.; García-Almagro, F. J.; Ruiz-Ros, J. A.; García-Conesa, M. T.; Tomás-Barberán, F. A.; Espín, J. C. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am. J. Cardiol. 2012, 110, 356-363. [CrossRef] [PubMed]
156. Zamora-Ros, R.; Urpi-Sarda, M.; Lamuela-Raventós, R. M.; Martínez-González, M. Á.; Salas-Salvadó, J.; Arós, F.; Fitó, M.; Lapetra, J.; Estruch, R.; Andres-Lacueva, C. PREDIMED study investigators. High urinary levels of resveratrol metabolites are associated with a reduction in the prevalence of cardiovascular risk factors in high-risk patients. Pharmacol. Res. 2012, 65, 615-620. [CrossRef] [PubMed]
157. Fujitaka, K.; Otani, H.; Jo, F.; Jo, H.; Nomura, E.; Iwasaki, M.; Nishikawa, M.; Iwasaka, T.; Das, D. K. Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr. Res. 2011, 31, 842-847. [CrossRef] [PubMed]
158. Wong, R. H.; Howe, P. R.; Buckley, J. D.; Coates, A. M.; Kunz, I.; Berry, N. M. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr. Metab. Cardiovasc. Dis. 2011, 21, 851-856. [CrossRef] [PubMed]
159. Karlsen, A.; Paur, I.; Bøhn, S. K.; Sakhi, A. K.; Borge, G. I.; Serafini, M.; Erlund, I.; Laake, P.; Tonstad, S.; Blomhoff, R. Bilberry juice modulates plasma concentration of NF-kappaB related inflammatory markers in subjects at increased risk of CVD. Eur. J. Nutr. 2010, 49, 345-355. [CrossRef] [PubMed]
160. Gresele, P.; Pignatelli, P.; Guglielmini, G.; Carnevale, R.; Mezzasoma, A. M.; Ghiselli, A.; Momi, S.; Violi, F. Resveratrol, at concentrations attainable with moderate wine consumption, stimulates human platelet nitric oxide production. J. Nutr. 2008, 138, 1602-1608. [PubMed]
161. Lekakis, J.; Rallidis, L. S.; Andreadou, I.; Vamvakou, G.; Kazantzoglou, G.; Magiatis, P.; Skaltsounis, A. L.; Kremastinos, D. T. Polyphenolic compounds from red grapes acutely improve endothelial function in patients with coronary heart disease. Eur. J. Cardiovasc. Prev. Rehabil. 2005, 12, 596-600. [CrossRef] [PubMed]